MedPath

BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 4:1

Drug Approvals

67

TGA:60
NMPA:7

Drug Approvals

Mavacamten Capsules

Product Name
迈凡妥
Approval Number
国药准字HJ20240014
Approval Date
Apr 24, 2024
NMPA

Mavacamten Capsules

Product Name
迈凡妥
Approval Number
国药准字HJ20240013
Approval Date
Apr 24, 2024
NMPA

Mavacamten Capsules

Product Name
迈凡妥
Approval Number
国药准字HJ20240012
Approval Date
Apr 24, 2024
NMPA

Mavacamten Capsules

Product Name
迈凡妥
Approval Number
国药准字HJ20240015
Approval Date
Apr 24, 2024
NMPA

Apixaban Tablets

Product Name
艾乐妥
Approval Number
国药准字HJ20170237
Approval Date
Sep 28, 2022
NMPA

Apixaban Tablets

Product Name
艾乐妥
Approval Number
国药准字HJ20170235
Approval Date
Sep 27, 2022
NMPA

Apixaban Tablets

Product Name
艾乐妥
Approval Number
国药准字HJ20170236
Approval Date
Sep 27, 2022
NMPA

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 4
1 (100.0%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.